Annovis Bio is a clinical stage company that develops drugs to treat neurodegeneration such as Alzheimer's Disease and Parkinson's Disease. Their lead compound, Buntanetap, has finished Phase 2a clinical trials and is in clinical trials for Down Syndrome and other chronic neurodegenerative disorders. The company is also developing ANVS405 and ANVS301 for protection against traumatic brain injury and stroke as well as increasing cognitive capability in later stages of AD and dementia.